Days after Johnson & Johnson CEO Alex Gorsky urged the pharmaceutical industry to better police itself on price increases, the drugmaker hiked list prices on a number of drugs in its portfolio, including Xarelto, Stelara and Zytiga, FiercePharma reports.
According to the report, a majority of the price increases on two dozen drugs fell within the 6 percent to 7 percent range.
Gorsky made the comments during the J.P. Morgan Healthcare Conference.
“If we don’t do this as an industry, I think there will be other alternatives that will be more onerous for us,” he said.
